Follow our financial story as we change the future of medicine.
On this page you can find financial reports, news and other information on CELLINK. Subscribe to our page to get all the latest updates.
Latest press releasesMore
August 13, 2020CELLINK announces strategic partnership with Carcinotech to advance 3D-bioprinting technology for cancer research
July 16, 2020RegulatoryBulletin from the extraordinary general meeting in CELLINK AB (publ)
July 14, 2020CELLINK and Kugelmeiers Ltd. announce strategic partnership for 3D printing cell spheroids
July 9, 2020RegulatoryQ3 19/20: Continued growth and Main market listing during an ongoing pandemic
June 24, 2020RegulatoryNotice of extraordinary general meeting of CELLINK AB (publ)
June 23, 2020CELLINK CELLINK has been granted a patent for "3D bioprinter and a 3D bioprinter system" from The Swedish Patent and Registration Office
June 9, 2020RegulatoryCELLINK has been granted a patent for "Cellulose Nanofibrillar Bioink for 3D Bioprinting for Cell Culturing, Tissue Engineering and Regenerative Medicine Applications" from USPTO
May 14, 2020CELLINK announces collaboration with AstraZeneca to utilize CELLINKs’ 3D-bioprinting technology for liver organoid culture
April 18, 2020CELLINK's founders informs about executing a call option
April 15, 2020RegulatoryThe conditions for listing of CELLINK on Nasdaq Stockholm have been fulfilled
April 15, 2020RegulatoryCELLINK publishes prospectus in connection with its listing on Nasdaq Stockholm
April 9, 2020RegulatoryQ2 19/20: Continued growth and global expansion during an increasing global crisis
April 3, 2020RegulatoryCELLINK AB (publ) approved for listing on Nasdaq Stockholm
March 31, 2020CELLINK AB (publ) receives an order of SEK 5,200,000 from the National Board of Health and Welfare in Sweden
March 25, 2020CELLINK launches a real-time qPCR instrument
March 22, 2020RegulatoryUpdate regarding COVID-19
March 4, 2020CELLINK has received a grant to develop a new organ-like in vitro model that can be used in drug development and testing for renal diseases.
February 3, 2020CELLINK announces extension of collaboration with AstraZeneca to use CELLINKs’ 3D-bioprinting and associated technology for drug discovery
January 29, 2020RegulatoryCELLINK has completed a directed share issue of SEK 377 million
January 29, 2020RegulatoryCELLINK announces intention to carry out a directed share issue of approximately 3,850,000 shares
January 20, 2020RegulatoryQ1 19/20: Strong sales growth and successful integration of acquisitions
January 9, 2020CELLINK is carrying out stock split (4:1)
December 23, 2019CELLINK signs agreement to expand its production area
December 18, 2019RegulatoryBulletin from the Annual General Meeting in CELLINK AB (publ)
December 13, 2019RegulatoryCELLINK’s board has set financial targets for the company
November 18, 2019RegulatoryNotice of annual general meeting of CELLINK AB (publ)
November 14, 2019Annual Report 2018/2019
November 4, 2019Bioprinting advanced skin architecture complete with blood vessels using CELLINK technology
October 24, 2019RegulatoryReport on Operations 2018-2019: Strategic acquisition and strong closing of the year
October 22, 2019Karolinska Institute study shows CELLINK’s I-DOT liquid-handling system can enable genetic cancer diagnostic research
October 14, 2019CELLINK is awarded Entrepreneur of the Year in Sweden 2019
October 2, 2019CELLINK and partner Prellis Biologics awarded Merck Innovation Award for cutting-edge technology designed to empower pharmaceutical research.
October 1, 2019CELLINK granted design patent for BIO X
September 3, 2019CELLINK announces a new product designed to be the most flexible six-printhead bioprinting platform on the market.
August 26, 2019RegulatoryCommunique from the Extraordinary General Meeting of CELLINK AB (publ)
August 8, 2019RegulatoryNotice of Extraordinary General Meeting of CELLINK AB (publ)
August 5, 2019RegulatoryCELLINK has entered an agreement to acquire single-cell dispensing company cytena GmbH.
July 11, 2018RegulatoryQuarterly report 3 for the period 1st of March – 31st of May and for the first 9 months
January 17, 2018RegulatoryQuarterly report 1 for the period 1st of September – 30th of November
October 19, 2017RegulatoryEnd of the year report for the period 1 of September – 31st of August and Quarterly report 4